A Look At Enovix (ENVX) Valuation As Analyst Optimism Meets Manufacturing And Profitability Risks

Recent analyst commentary on Enovix (ENVX) is highlighting a mix of long term optimism around its high energy density lithium ion batteries, along with caution about manufacturing hurdles, negative margins, and cash burn tied to scaling production.

See our latest analysis for Enovix.

The share price has been under pressure, with a 1 month share price return showing an 18.32% decline and a year to date share price return showing a 38.40% decline. The 1 year total shareholder return of 42.49% decline signals fading momentum as investors weigh long term battery potential against execution and funding risks.

If Enovix’s recent swings have you considering where else growth stories could emerge, it may be worth scanning 35 AI infrastructure stocks for other power hungry AI infrastructure plays tied to rising compute demand.

With Enovix shares at US$4.86 and an analyst price target of US$14.45, the gap looks wide on paper. Yet ongoing losses and execution risks are front and center, so is this a mispriced growth story or is the market already factoring in what comes next?

Most Popular Narrative: 68.4% Undervalued

At a last close of $4.86 versus a narrative fair value of $15.39, Enovix is framed as heavily discounted, with that gap hinging on aggressive future assumptions.

The analysts have a consensus price target of $26.909 for Enovix based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $100.0, and the most bearish reporting a price target of just $10.0.

Read the complete narrative.

Want to see what justifies a fair value more than triple the current price? The narrative leans on rapid revenue expansion, a sharp profitability shift and a rich earnings multiple. The exact mix of growth, margins and required return is where the story gets interesting.

Result: Fair Value of $15.39 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that upside story hinges on Enovix proving it can scale high volume manufacturing without costly delays, as well as securing firm customer qualifications for its smartphone batteries.

Find out about the key risks to this Enovix narrative.

Another Way to Look at Valuation

The narrative fair value of $15.39 paints Enovix as heavily undervalued, but the market is telling a different story when you look at sales. At a P/S ratio of 32.3x versus 2.1x for the US Electrical industry and a fair ratio of 3.6x, the shares screen as very expensive on current revenue. That kind of gap can be a reward if future sales justify it, or a risk if expectations cool.

Before leaning on any single yardstick, it helps to see how the current price lines up with the full valuation breakdown and what that implies if sentiment or growth assumptions change: See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and caution leaves you undecided, take a closer look at the numbers now and shape your own view using the 2 key rewards

Looking for more investment ideas?

If Enovix has sharpened your thinking, do not stop there. Use the screener to line up other clear, data driven opportunities that keep your watchlist evolving.

• Target potential mispricings by scanning 52 high quality undervalued stocks that combine quality fundamentals with prices the market may be overlooking.
• Strengthen the defensive side of your portfolio by reviewing solid balance sheet and fundamentals stocks screener (39 results) that can help you stay comfortable when volatility picks up.
• Spot early stage opportunities by tracking 33 elite penny stocks with strong financials that pair smaller market caps with stronger financial profiles than many peers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com